import type { Metadata } from 'next';
import { Breadcrumbs } from '@/components/breadcrumbs';
import { AutoLink } from '@/components/auto-link';
import Link from 'next/link';
import Image from 'next/image';
import { ChevronRight, Calendar, User, ArrowLeft, ArrowRight, Clock, ShieldAlert, BookOpen, AlertCircle, Scale, FlaskConical, TrendingUp, Landmark } from 'lucide-react';
import { ShareBar } from '@/components/share-bar';
import { CiteThisPage } from '@/components/cite-page';
import { AuthorBio } from '@/components/author-bio';
import { FeedbackModal } from '@/components/feedback-modal';
import { SHORT_DISCLAIMER } from '@/data/constants';
import { LibraryCallout } from '@/components/library-callout';
import { getAuthorSlug } from '@/data/authors';
import { BlogVendorCallout } from '@/components/blog-vendor-callout';

const POST_TITLE = '14 Peptides Are Going Legal Again in 2026: What the FDA Reclassification Means';
const POST_DESC = 'The FDA is reclassifying 14 restricted peptides from Category 2 back to Category 1 in 2026. Learn which peptides are affected, what it means for patients and clinics, and how to access them safely.';
const AUTHOR = 'PeptideX Editorial';
const DATE_PUB = '2026-04-11';
const DATE_MOD = '2026-04-11';
const SLUG = 'fda-peptide-reclassification-2026';
const CANONICAL = `https://peptidex.app/blog/${SLUG}`;

export const metadata: Metadata = {
  title: `${POST_TITLE} | PeptiDex Blog`,
  description: POST_DESC,
  keywords: ['FDA peptide reclassification 2026', 'peptides legal 2026', 'BPC-157 legal', 'Category 1 peptides', 'RFK peptides', 'peptide therapy 2026', 'GHK-Cu', 'compounding pharmacy peptides'],
  alternates: {
    canonical: CANONICAL,
  },
  openGraph: {
    title: POST_TITLE,
    description: POST_DESC,
    url: CANONICAL,
    type: 'article',
    images: [{ url: 'https://peptidex.app/images/blog/fda_reclassification_2026.png', width: 1200, height: 630 }],
  },
  twitter: {
    card: 'summary_large_image',
    title: POST_TITLE,
    description: 'The biggest regulatory shift in peptide access in a decade. 14 peptides are returning to legal compounding status.',
    images: ['https://peptidex.app/images/blog/fda_reclassification_2026.png'],
  },
};

const blogSchema = {
  '@context': 'https://schema.org',
  '@type': 'BlogPosting',
  headline: POST_TITLE,
  description: POST_DESC,
  author: { '@type': 'Organization', name: 'PeptideX Research', url: 'https://peptidex.app' },
  publisher: {
    '@type': 'Organization',
    name: 'PeptideX',
    logo: { '@type': 'ImageObject', url: 'https://peptidex.app/favicon.ico' },
  },
  image: 'https://peptidex.app/images/blog/fda_reclassification_2026.png',
  datePublished: `${DATE_PUB}T12:00:00Z`,
  dateModified: `${DATE_MOD}T12:00:00Z`,
  mainEntityOfPage: { '@type': 'WebPage', '@id': CANONICAL },
};

const breadcrumbSchema = {
  '@context': 'https://schema.org',
  '@type': 'BreadcrumbList',
  itemListElement: [
    { '@type': 'ListItem', position: 1, name: 'Home', item: 'https://peptidex.app/' },
    { '@type': 'ListItem', position: 2, name: 'Blog', item: 'https://peptidex.app/blog' },
    { '@type': 'ListItem', position: 3, name: '14 Peptides Going Legal 2026', item: CANONICAL },
  ],
};

const faqSchema = {
  '@context': 'https://schema.org',
  '@type': 'FAQPage',
  mainEntity: [
    {
      '@type': 'Question',
      name: 'Which peptides are being reclassified by the FDA in 2026?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Approximately 14 of 19 previously restricted peptides are expected to move from Category 2 to Category 1, including BPC-157, Thymosin Alpha-1, TB-500, CJC-1295, Ipamorelin, AOD-9604, GHK-Cu, MOTS-c, Selank, Semax, KPV, Epitalon, Kisspeptin-10, and GHRP-6.',
      },
    },
    {
      '@type': 'Question',
      name: 'Does the FDA peptide reclassification mean these peptides are FDA-approved?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'No. Reclassification from Category 2 to Category 1 allows licensed compounding pharmacies to legally prepare these peptides with a physician\u2019s prescription. It does not mean they have undergone FDA approval through clinical trials.',
      },
    },
    {
      '@type': 'Question',
      name: 'When will the FDA peptide reclassification take effect?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'HHS Secretary RFK Jr. announced the intended reclassification on February 27, 2026. As of April 2026, the FDA has not yet published the formal updated Category 1 list, so the legal status remains in transition.',
      },
    },
    {
      '@type': 'Question',
      name: 'Are gray-market "research use only" peptides safe?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'Quality analyses have found significant rates of inaccurate dosing, contamination, and mislabeled compounds among unregulated peptide products sold online. Working with a licensed physician and FDA-registered compounding pharmacy is the safest way to access peptide therapy.',
      },
    },
    {
      '@type': 'Question',
      name: 'What is the most popular peptide in 2026?',
      acceptedAnswer: {
        '@type': 'Answer',
        text: 'By search volume, tirzepatide leads with approximately 1 million monthly searches. Among non-weight-loss peptides, BPC-157 is the most popular at around 165,000 monthly searches, while GHK-Cu is the fastest-growing with over 1,000% year-over-year search growth.',
      },
    },
  ],
};

/* ─── PEPTIDE DATA ─────────────────────────────────────────────────── */
const PEPTIDES = [
  { name: 'BPC-157', desc: 'Tissue repair, gut healing, anti-inflammatory support' },
  { name: 'Thymosin Alpha-1', desc: 'Immune modulation, approved in 30+ countries outside the U.S.' },
  { name: 'TB-500', desc: 'Cell migration, wound healing, muscle recovery' },
  { name: 'CJC-1295', desc: 'Growth hormone\u2013releasing hormone analog' },
  { name: 'Ipamorelin', desc: 'Growth hormone secretagogue for sleep & metabolism' },
  { name: 'AOD-9604', desc: 'Fat metabolism peptide fragment' },
  { name: 'GHK-Cu', desc: 'Copper-binding peptide for skin, hair, and anti-aging' },
  { name: 'MOTS-c', desc: 'Mitochondrial peptide for metabolic regulation' },
  { name: 'Selank', desc: 'Neuropeptide studied for anxiety and cognition' },
  { name: 'Semax', desc: 'Neuropeptide for cognitive function and focus' },
  { name: 'KPV', desc: 'Anti-inflammatory tripeptide derived from \u03B1-MSH' },
  { name: 'Epitalon', desc: 'Telomerase-activating tetrapeptide for longevity' },
  { name: 'Kisspeptin-10', desc: 'Hormonal signaling and reproductive health' },
  { name: 'GHRP-6', desc: 'Growth hormone-releasing peptide' },
];

const TIMELINE = [
  { date: 'Late 2023', text: 'The FDA moves 19 widely used peptides to its Category 2 restricted list, citing safety concerns including immunogenicity risks, manufacturing impurities, and insufficient human clinical data.' },
  { date: '2024 \u2013 2025', text: 'Consumer demand goes underground. Gray-market peptide imports from overseas surge dramatically. FDA testing reveals significant contamination and dosing issues in online products.' },
  { date: 'September 2024', text: 'Five peptides \u2014 CJC-1295, Ipamorelin, Thymosin Alpha-1, AOD-9604, and Selank \u2014 are removed from Category 2 and referred to the PCAC for formal review.' },
  { date: 'February 27, 2026', text: 'HHS Secretary RFK Jr. announces on the Joe Rogan Experience that approximately 14 of 19 restricted peptides will move back to Category 1, restoring access through licensed compounding pharmacies.' },
  { date: 'April 2026 (Now)', text: 'The FDA has not yet published the formal updated Category 1 list. The peptides remain technically under Category 2 restrictions until official rulemaking is completed.' },
];

const STATS = [
  { num: '14', label: 'Peptides Reclassified' },
  { num: '10.1M', label: 'Monthly Searches' },
  { num: '$328M', label: 'Gray Market (2025)' },
  { num: '1,016%', label: 'GHK-Cu Growth YoY' },
];

export default function FDAReclassificationArticle() {
  return (
    <div className="max-w-4xl mx-auto px-4 py-8 md:py-12 relative space-y-12">
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(blogSchema) }} />
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(breadcrumbSchema) }} />
      <script type="application/ld+json" dangerouslySetInnerHTML={{ __html: JSON.stringify(faqSchema) }} />

      {/* Breadcrumbs */}
      <Breadcrumbs items={[
        { name: 'Home', url: 'https://peptidex.app/' },
        { name: 'Blog', url: 'https://peptidex.app/blog' },
        { name: '14 Peptides Going Legal Again' }
      ]} />

      {/* Back Button */}
      <Link href="/blog" className="inline-flex items-center gap-2 text-sm text-zinc-400 hover:text-white transition-colors mb-8 group">
        <ArrowLeft className="w-4 h-4 group-hover:-translate-x-1 transition-transform" />
        Back to Blog
      </Link>

      {/* ═══════ HERO IMAGE ═══════ */}
      <div className="relative w-full h-56 md:h-72 rounded-2xl overflow-hidden border border-zinc-800 mb-4">
        <Image
          src="/images/blog/fda_reclassification_2026.png"
          alt="FDA Peptide Reclassification 2026 — scales of justice intertwined with peptide molecular structures"
          fill
          className="object-cover"
          sizes="(max-width: 768px) 100vw, 896px"
          unoptimized
          priority
        />
        <div className="absolute inset-0 bg-gradient-to-t from-zinc-950/70 via-transparent to-transparent" />
      </div>

      {/* ═══════ TOP DISCLAIMER ═══════ */}
      <div className="rounded-xl bg-amber-950/25 border border-amber-500/20 p-4">
        <div className="flex items-start gap-2">
          <ShieldAlert className="w-5 h-5 text-amber-500 flex-shrink-0 mt-0.5" />
          <p className="text-sm text-amber-400/80 leading-relaxed font-medium">
            <strong>EDUCATIONAL CONTENT:</strong> {SHORT_DISCLAIMER}
          </p>
        </div>
      </div>

      {/* ═══════ ARTICLE HEADER ═══════ */}
      <header className="space-y-6">
        <div className="flex items-center gap-3">
          <span className="px-3 py-1 text-[10px] font-bold uppercase tracking-widest bg-rose-500/15 text-rose-300 rounded-full border border-rose-500/30">
            Regulatory Update
          </span>
          <span className="text-[10px] font-bold uppercase tracking-widest text-zinc-500">April 2026</span>
        </div>
        <h1 className="text-3xl md:text-4xl lg:text-5xl font-extrabold tracking-tight text-zinc-100 leading-tight">
          14 Peptides Are Going Legal Again: What the 2026 FDA <span className="text-rose-400">Reclassification</span> Actually Means
        </h1>
        <div className="flex flex-wrap items-center gap-4 text-sm text-zinc-400 border-t border-b border-zinc-800/50 py-4">
          <div className="flex items-center gap-2">
            <User className="w-4 h-4 text-rose-400" />
            <Link href={`/about/${getAuthorSlug(AUTHOR)}`} className="font-semibold text-zinc-200 hover:text-violet-400 transition-colors">{AUTHOR}</Link>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <Calendar className="w-4 h-4 text-zinc-500" />
            <span>April 11, 2026</span>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <Clock className="w-4 h-4 text-zinc-500" />
            <span>10 min read</span>
          </div>
          <div className="w-1.5 h-1.5 rounded-full bg-zinc-700" />
          <div className="flex items-center gap-2">
            <Scale className="w-4 h-4 text-rose-400" />
            <span className="text-rose-300 font-medium">Health &amp; Science</span>
          </div>
        </div>
        <ShareBar title={POST_TITLE} url={`https://peptidex.app/blog/fda-peptide-reclassification-2026`} />
      </header>

      {/* ═══════ MAIN CONTENT ═══════ */}
      <AutoLink>
      <article className="prose prose-invert prose-zinc max-w-none prose-headings:font-bold prose-h2:text-2xl prose-h2:text-zinc-200 prose-h2:mt-12 prose-h2:mb-6 prose-h2:pb-2 prose-h2:border-b prose-h2:border-zinc-800 prose-p:text-zinc-300 prose-p:leading-loose prose-a:text-violet-400 prose-a:no-underline hover:prose-a:underline prose-strong:text-zinc-200 prose-strong:font-bold prose-ul:text-zinc-300 prose-li:marker:text-rose-500">

        <p className="lead text-xl text-zinc-300 font-medium">
          In what may be the most consequential regulatory shift for peptide therapy in over a decade, approximately 14 previously restricted peptides are poised to return to legal compounding status in the United States. The announcement, made by HHS Secretary Robert F. Kennedy Jr. on the Joe Rogan Experience podcast on February 27, 2026, has sent shockwaves through the wellness, longevity, and functional medicine communities &mdash; and raised critical questions that anyone interested in peptide therapy should understand.
        </p>

        <p>
          This isn&apos;t a fringe story anymore. U.S. peptide-related searches hit <strong>10.1 million per month</strong> by January 2026, and the gray market for imported peptides ballooned to an estimated <strong>$328 million in 2025</strong>. The regulatory pendulum is now swinging back &mdash; but the details matter far more than the headlines suggest.
        </p>

        {/* ═══════ STATS ROW ═══════ */}
        <div className="not-prose grid grid-cols-2 md:grid-cols-4 gap-3 my-10">
          {STATS.map((s) => (
            <div key={s.label} className="text-center bg-zinc-900/60 border border-zinc-800 rounded-xl p-5">
              <div className="text-2xl md:text-3xl font-extrabold text-rose-400 mb-1">{s.num}</div>
              <div className="text-[10px] font-bold uppercase tracking-widest text-zinc-500">{s.label}</div>
            </div>
          ))}
        </div>

        <h2 id="timeline">How We Got Here: A Brief Timeline</h2>
        <p>To understand why this reclassification matters, you need to understand what happened in 2023 &mdash; and the unintended consequences that followed.</p>

        {/* ═══════ TIMELINE ═══════ */}
        <div className="not-prose relative pl-8 my-10 space-y-8 border-l-2 border-zinc-800">
          {TIMELINE.map((item, i) => (
            <div key={i} className="relative">
              <div className="absolute -left-[25px] top-1.5 w-3 h-3 rounded-full bg-rose-500 border-2 border-zinc-950 ring-4 ring-zinc-950" />
              <div className="text-[11px] font-bold uppercase tracking-widest text-rose-400 mb-2">{item.date}</div>
              <p className="text-sm text-zinc-400 leading-relaxed">{item.text}</p>
            </div>
          ))}
        </div>

        <h2 id="which-peptides">Which Peptides Are Coming Back?</h2>
        <p>
          Based on the HHS announcement and analyses from regulatory experts, these are the 14 peptides expected to return to Category 1 compounding eligibility. Each serves a distinct biological function, and their combined re-entry represents a meaningful expansion of what physicians can legally prescribe through compounding pharmacies.
        </p>

        {/* ═══════ PEPTIDE GRID ═══════ */}
        <div className="not-prose grid grid-cols-1 sm:grid-cols-2 lg:grid-cols-3 gap-3 my-10">
          {PEPTIDES.map((p) => (
            <div key={p.name} className="bg-zinc-900/40 border border-zinc-800 rounded-xl p-4 hover:border-rose-500/30 transition-colors group">
              <h4 className="text-sm font-bold text-zinc-100 mb-1 group-hover:text-rose-400 transition-colors">{p.name}</h4>
              <p className="text-xs text-zinc-500 leading-relaxed">{p.desc}</p>
            </div>
          ))}
        </div>

        <h2 id="category-1">What &ldquo;Category 1&rdquo; Actually Means (And What It Doesn&apos;t)</h2>
        <p>
          This is where the nuance lives &mdash; and where many headlines get it wrong. Moving from Category 2 to Category 1 does <strong>not</strong> mean these peptides are FDA-approved drugs. The distinction is critical for patients and providers alike.
        </p>

        {/* ═══════ CALLOUT BOX ═══════ */}
        <div className="not-prose my-8 rounded-2xl bg-zinc-900/60 border border-violet-500/20 p-6 space-y-4">
          <div className="flex items-start gap-3">
            <span className="px-2 py-0.5 text-[10px] font-bold uppercase tracking-widest bg-emerald-500/20 text-emerald-400 rounded border border-emerald-500/30">Category 1</span>
            <p className="text-sm text-zinc-300 leading-relaxed">A bulk drug substance may be compounded by licensed pharmacies under a valid physician prescription while it remains under FDA evaluation. This is a <em>regulatory permission to compound</em> &mdash; not a certification of safety, efficacy, or standardized dosing.</p>
          </div>
          <div className="flex items-start gap-3">
            <span className="px-2 py-0.5 text-[10px] font-bold uppercase tracking-widest bg-rose-500/20 text-rose-400 rounded border border-rose-500/30">Category 2</span>
            <p className="text-sm text-zinc-300 leading-relaxed">The FDA has identified potential safety risks, and the substance is currently restricted from routine compounding.</p>
          </div>
          <div className="flex items-start gap-3">
            <span className="px-2 py-0.5 text-[10px] font-bold uppercase tracking-widest bg-blue-500/20 text-blue-400 rounded border border-blue-500/30">FDA Approved</span>
            <p className="text-sm text-zinc-300 leading-relaxed">Requires formal Phase I, II, and III clinical trials, an approved New Drug Application (NDA), and validated manufacturing &mdash; none of which apply to these reclassified peptides.</p>
          </div>
        </div>

        <p>
          In practical terms, reclassification means that a physician who determines a peptide could benefit a patient can write a prescription, and a licensed compounding pharmacy operating under USP 797 and 795 standards can legally fill it. The quality, dosing, and oversight responsibility shifts back to the clinical relationship between patient and provider &mdash; which many in the functional medicine space argue is exactly where it belongs.
        </p>

        <h2 id="safety-debate">The Safety Debate: Two Perspectives</h2>
          <p className="p-4 bg-violet-900/10 border border-violet-500/20 rounded-xl my-6 text-zinc-300">
            For researchers sourcing these compounds, <a href="https://aminoclub.com?utm_source=affiliate_marketing&code=PEPTIDEX" target="_blank" rel="noopener noreferrer" className="font-semibold text-violet-400 hover:underline">Amino Club provides COA-verified peptides with documented purity testing. Browse peptides &rarr;</a>
          </p>

        <p>
          The reclassification is not without controversy. Former FDA officials have pushed back on the characterization that the original Category 2 designations were baseless, noting that insufficient clinical data is itself a safety concern. ProPublica reported that some officials believe reversing the restrictions could lend an unwarranted appearance of safety to compounds with limited human trial data.
        </p>
        <p>
          On the other hand, proponents of reclassification point to a paradox that emerged during the restriction period: banning compounds from regulated pharmacies didn&apos;t eliminate demand &mdash; it pushed consumers toward unregulated gray-market sources with documented contamination issues. The argument is straightforward &mdash; supervised access through licensed pharmacies, even for compounds without full FDA approval, is materially safer than the alternative that already exists.
        </p>
        <p>
          Both perspectives deserve serious consideration. The honest answer is that for most of these 14 peptides, we have extensive preclinical data, decades of practitioner experience, and a strong biological rationale &mdash; but limited large-scale human clinical trial evidence. Patients considering peptide therapy should understand this clearly.
        </p>

        <h2 id="top-peptides">The Peptides Driving the Most Interest in 2026</h2>

        <h3 className="flex items-center gap-2 text-violet-300 border-b border-zinc-800 pb-2">
          <FlaskConical className="w-5 h-5" /> BPC-157: The Recovery Powerhouse
        </h3>
        <p>
          BPC-157 remains the most-searched non-weight-loss peptide in the United States, with approximately <strong>165,000 monthly searches</strong>. Derived from a protein found in gastric juice, it has been studied extensively in animal models for tissue repair across musculoskeletal, gastrointestinal, and neurological systems. Its return to legal compounding status is arguably the most anticipated among practitioners.
        </p>

        <h3 className="flex items-center gap-2 text-emerald-300 border-b border-zinc-800 pb-2">
          <TrendingUp className="w-5 h-5" /> GHK-Cu: The Breakout Star
        </h3>
        <p>
          With a staggering year-over-year search growth rate exceeding <strong>1,000%</strong>, the copper-binding tripeptide GHK-Cu is the fastest-growing peptide in consumer interest. Naturally occurring in human plasma, it has been studied in over 50 published papers spanning skin biology, wound healing, and gene expression. New randomized controlled trials initiated in 2025 are adding to this evidence base, and its applications in skincare and hair regrowth have driven viral interest across social media platforms.
        </p>

        <h3 className="flex items-center gap-2 text-amber-300 border-b border-zinc-800 pb-2">
          <FlaskConical className="w-5 h-5" /> MOTS-c: The Mitochondrial Frontier
        </h3>
        <p>
          MOTS-c represents a fascinating category &mdash; peptides encoded not by nuclear DNA, but by the mitochondrial genome. First described in 2015 in <em>Cell Metabolism</em>, this 16-amino-acid peptide has been studied for metabolic regulation and exercise-mimicking effects at the molecular level. It sits at the intersection of two powerful trends: the longevity research movement and the growing scientific interest in mitochondria as active signaling organs.
        </p>

        {/* ═══════ CTA EMBED ═══════ */}
        <div className="not-prose my-10 rounded-2xl bg-gradient-to-br from-violet-900/40 to-zinc-900 border border-violet-500/30 p-6 shadow-xl relative overflow-hidden group">
          <div className="absolute top-0 right-0 w-32 h-32 bg-violet-500/10 blur-[50px] rounded-full pointer-events-none transition-all group-hover:bg-violet-500/20" />
          <h4 className="text-xl font-bold text-zinc-100 mb-2 flex flex-wrap items-center gap-2">
            <AlertCircle className="w-5 h-5 text-violet-400" /> Looking for verified peptide sources?
          </h4>
          <p className="text-sm text-zinc-300 mb-6 max-w-lg leading-relaxed">
            We aggregate and review the top peptide synthesis labs based strictly on independent HPLC mass spectrometry, pricing, and fulfillment speed.
          </p>
          <Link
            href="/vendors"
            rel="nofollow noopener sponsored"
            className="inline-flex items-center justify-center gap-2 px-6 py-3 rounded-xl bg-violet-600 hover:bg-violet-500 text-white font-bold transition-all shadow-lg hover:shadow-violet-500/25"
          >
            Compare Trusted Vendors <ArrowRight className="w-5 h-5" />
          </Link>
        </div>

        <h2 id="how-to-access">How to Access Peptide Therapy Safely in 2026</h2>
        <p>
          If and when the formal reclassification is published, patients interested in peptide therapy should prioritize safety through a few key principles.
        </p>
        <p>
          First, <strong>work with a licensed physician</strong> &mdash; ideally one with training in functional, integrative, or longevity medicine &mdash; who can evaluate your health history, order appropriate baseline labs, and design a monitored protocol. Peptide therapy is not a supplement you pick up at a health food store; it requires clinical oversight.
        </p>
        <p>
          Second, <strong>ensure your peptides are sourced from a U.S.-based, FDA-registered compounding pharmacy</strong> that operates under USP 797 and 795 compounding standards. Ask for batch-specific Certificates of Analysis (COAs) from third-party labs confirming purity above 98% by HPLC.
        </p>
        <p>
          Third, <strong>approach gray-market peptides labeled &ldquo;research use only&rdquo; with extreme caution.</strong> Quality testing has repeatedly shown that a significant share of online peptide products contain inaccurate dosing, contamination, or entirely different compounds than what&apos;s listed on the label.
        </p>

        <h2 id="broader-landscape">What This Means for the Broader Peptide Landscape</h2>
        <p>
          The reclassification doesn&apos;t exist in isolation. It arrives at a moment when FDA-approved peptide drugs like semaglutide and tirzepatide have already transformed public perception of what peptides can do. Over 80 peptide-based drugs now carry FDA approval, and the success of GLP-1 receptor agonists has normalized the idea of injectable peptide therapies for millions of Americans.
        </p>
        <p>
          At the same time, the research pipeline is expanding. Triple-receptor agonists like retatrutide are in Phase 3 trials. AI-driven drug discovery is accelerating the identification of novel peptide candidates. Cell-penetrating peptide technology is opening doors to applications in neuroprotection and even gene editing delivery. The 2026 landscape is fundamentally different from even two years ago.
        </p>
        <p>
          For patients, the key takeaway is this: peptide therapy is entering a more accessible &mdash; but not a less complex &mdash; era. The science is promising. The regulatory environment is evolving. And the difference between a good outcome and a risky one comes down to the quality of your provider, your pharmacy, and your willingness to stay informed.
        </p>

      </article>
      </AutoLink>

      {/* ═══════ FAQ SECTION ═══════ */}
      
      {/* Explore in Our Library */}
      <LibraryCallout currentSlug="fda-peptide-reclassification-2026" peptides={[{"name":"BPC-157","slug":"bpc-157"},{"name":"GHK-Cu","slug":"ghk-cu"},{"name":"Thymosin Alpha-1","slug":"thymosin-alpha-1"}]} />
{/* Citations */}
      <div className="mb-12">
        <CiteThisPage title={POST_TITLE} url={`https://peptidex.app/blog/fda-peptide-reclassification-2026`} />
      </div>

      <section className="border-t border-zinc-800 pt-12 mt-12 pb-8">
        <h2 className="text-2xl font-bold text-zinc-100 text-center mb-8">Frequently Asked Questions</h2>
        <div className="max-w-3xl mx-auto space-y-4">
          {faqSchema.mainEntity.map((q, idx) => (
            <div key={idx} className="bg-zinc-900/60 border border-zinc-800 rounded-xl p-6">
              <h3 className="text-md font-bold text-zinc-200 mb-3">{q.name}</h3>
              <p className="text-zinc-400 text-sm leading-relaxed">{q.acceptedAnswer.text}</p>
            </div>
          ))}
        </div>
      </section>

      {/* ═══════ AUTHOR BIO ═══════ */}
      
      <ShareBar title={POST_TITLE} url={`https://peptidex.app/blog/fda-peptide-reclassification-2026`} />
      <BlogVendorCallout />
      <AuthorBio name={AUTHOR} />

      {/* Fact-checked date + Feedback */}
      <div className="flex items-center justify-between pt-6 border-t border-zinc-800/50 text-xs text-zinc-600">
        <span>Last fact-checked: <time dateTime="2026-04-11">2026-04-11</time></span>
        <FeedbackModal pageUrl="https://peptidex.app/blog/fda-peptide-reclassification-2026" />
      </div>

      {/* ═══════ DISCLAIMER ═══════ */}
      <div className="mt-16 p-6 rounded-2xl bg-zinc-900 border border-zinc-800 flex flex-col gap-2">
        <p className="text-xs text-zinc-500 uppercase tracking-widest font-bold">Disclaimer</p>
        <p className="text-sm text-zinc-400 leading-relaxed italic">
          This article is for informational and educational purposes only. It does not constitute medical advice. Peptide therapies discussed here are not FDA-approved drugs. Consult a licensed healthcare provider before beginning any peptide protocol. All regulatory information reflects publicly available data as of April 11, 2026.
        </p>
      </div>
    </div>
  );
}
